Can the acute-phase reactant proteins be used as cancer biomarkers?
The association between the acute-phase reactant proteins (APRPs) and cancer has long been established. There have been numerous reports correlating altered levels of various APRPs with different types of cancers. However, researchers are often quick to dismiss the use of these APRPs as potential biomarkers for the diagnosis and monitoring of cancer because alterations in APRP concentrations are observed in a wide range of diseases. Recent progress in proteomics studies which profiled the serum proteins of cancer patients and those of normal individuals indicated that the altered APRP expressions were different for distinct types, subtypes, and even stages of cancer. Interestingly, these data are in agreement with those observed earlier using immunochemical and biochemical assays. In view of this compelling association of different patterns of APRPs with various types of cancers and in an apparent shift of paradigm, we present in this review some indications that APRP fingerprinting may be used as complementary cancer biomarkers.
Pang
Wei Wei
WW
University of Malaya Centre for Proteomics Research, Faculty of Medicine, University of Malaya, Kuala Lumpur - Malaysia.
Abdul-Rahman
Puteri Shafinaz
PS
Wan-Ibrahim
Wan Izlina
WI
Hashim
Onn Haji
OH
D000209:Acute-Phase Proteins / Q000032:analysis* / Q000276:immunology / Q000502:physiology; D014408:Biomarkers, Tumor / Q000097:blood*; D016207:Cytokines / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000276:immunology; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology; D010449:Peptide Mapping; D040901:Proteomics
D000209:Acute-Phase Proteins; D014408:Biomarkers, Tumor; D016207:Cytokines